The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Production of therapeutic antibodies with controlled fucosylation
Open accessAbstract
The clinical success of therapeutic antibodies is demonstrated by the number of antibody therapeutics that have been brought to market and the increasing number of therapeutic antibodies in development. Recombinant antibodies are molecular-targeted therapeutic agents and represent a major new class of drugs. However, it is still very important to optimize and maximize the clinical efficacy of therapeutic antibodies, in part to help lower the cost of therapeutic antibodies by potentially reducing the dose or the duration of treatment. Clinical trials using therapeutic antibodies fully lacking core fucose residue in the Fc oligosaccharides are currently underway, and their remarkable physiological activities in humans in vivo have attracted attention as next-generation therapeutic antibody approaches with improved efficacy. Thus, an industrially applicable antibody production process that provides consistent yields of fully non-fucosylated antibody therapeutics with fixed quality has become a key goal in the successful development of next-generation therapeutic agents. In this article, we review the current technologies for production of therapeutic antibodies with control of fucosylation of the Fc N-glycans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Self-citationMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Wang, X., Inoue, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507375102 · Cited by 476
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00006-7 · Cited by 421
Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974512425 · Cited by 304
Imai-Nishiya (2007) · doi:10.1186/1472-6750-7-84 · Cited by 157
Cited by
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Biological functions of fucose in mammals
Schneider, M., Al-Shareffi, E., & Haltiwanger, R. S. (2017) · Glycobiology · doi:10.1093/glycob/cwx034 · Cited by 431
Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
Binnewies, M., Pollack, J. L., Rudolph, J., Dash, S., Abushawish, M., Lee, T., Jahchan, N. S., Canaday, P., Lu, E., Norng, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109844 · Cited by 365
Enzymes in the Synthesis of Glycoconjugates
Schmaltz, R. M., Hanson, S. R., & Wong, C.-H. (2011) · Chemical Reviews · doi:10.1021/cr200113w · Cited by 283
Metadata
- Authors
- Yamane-Ohnuki, N., & Satoh, M.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 1
- Issue
- 3
- Pages
- 230-236
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2078490791
- Cited by
- 170
- References
- 9
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Production of therapeutic antibodies with controlled fucosylation. https://app.cochat.ai/papers/10.4161/mabs.1.3.8328
- The paper
- Yamane-Ohnuki, N., & Satoh, M. (2009). Production of therapeutic antibodies with controlled fucosylation. mAbs. https://doi.org/10.4161/mabs.1.3.8328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
